Company intelligence / Profile preview

Innovega

Bellevue, Washington, United States

Ownership: Private
Development stage: Other

Overview

Innovega's eMacula™ system and smart glasses have shown clinically validated results, achieving up to 20/20 visual acuity in low vision patients through independent testing by Ohio State University College of Optometry. Technology is on the regulatory path to FDA market clearance for visually impaired patients with myopia-related retinal degeneration.[1][2][5]

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Assistive Medical Devices

Partnerships

Global supplier of technology for visually impaired (deal struck)

Beyond the preview

Go deeper on Innovega.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovega.

Explore the full profile